10 _ O
11 _ O
GLAND _ O
PHARMA _ O
LIMITED _ O
Annual _ B-key
Report _ I-key
2021 _ O
- _ O
22 _ O
Financial _ O
StatementsCorporate _ O
Overview _ O
06 _ O
- _ O
49 _ O
Statutory _ B-key
Reports _ I-key
50 _ O
- _ O
116 _ O
117 _ O
- _ O
237 _ O
Letter _ O
from _ O
the _ O
MD _ O
and _ O
CEO _ O
Dear _ O
Shareholders _ O
, _ O
Our _ O
inherent _ O
ability _ O
to _ O
capitalise _ B-key
on _ O
emerging _ O
opportunities _ O
with _ O
a _ O
broad _ O
product _ O
portfolio _ O
and _ O
differentiated _ O
business _ B-key
model _ I-key
continues _ O
to _ O
pave _ O
the _ O
way _ O
for _ O
a _ O
better _ O
and _ O
sustainable _ O
future _ O
for _ O
Gland _ O
Pharma _ O
. _ O

We _ O
remain _ O
committed _ O
to _ O
uphold _ O
the _ O
trust _ O
and _ O
support _ O
of _ O
all _ O
our _ O
stakeholders _ B-key
with _ O
a _ O
quality-first _ O
approach _ O
in _ O
all _ O
that _ O
we _ O
do _ O
. _ O

The _ O
year _ O
2021 _ O
saw _ O
the _ O
global _ B-key
economy _ I-key
take _ O
firm _ O
steps _ O
towards _ O
recovery _ O
, _ O
despite _ O
the _ O
fact _ O
that _ O
the _ O
spread _ O
of _ O
virus _ O
mutants _ O
remained _ O
a _ O
concern _ O
. _ O

The _ O
pace _ O
of _ O
economic _ B-key
recovery _ O
remained _ O
divergent _ O
across _ O
geographies _ O
, _ O
depending _ O
upon _ O
the _ O
access _ O
to _ O
vaccines _ O
and _ O
the _ O
fiscal _ O
and _ O
monetary _ O
stimulus _ O
measures _ O
provided _ O
. _ O

Growth _ O
in _ O
economy _ O
, _ O
production _ B-key
output _ O
and _ O
stronger _ O
employment _ O
figures _ O
indicate _ O
improved _ O
demand _ B-key
conditions _ O
globally _ O
. _ O

However _ O
, _ O
global _ B-key
supply _ I-key
chain _ I-key
disruption _ O
, _ O
rising _ O
inflationary _ B-key
pressures _ O
and _ O
elevated _ O
geopolitical _ O
tensions _ O
are _ O
having _ O
an _ O
impact _ O
on _ O
the _ O
momentum _ O
of _ O
the _ O
recovery _ O
. _ O

The _ O
Indian _ O
economy _ O
also _ O
continued _ O
to _ O
register _ O
sustained _ O
recovery _ O
with _ O
a _ O
steady _ O
drop _ O
in _ O
new _ O
COVID _ B-key
- _ I-key
19 _ I-key
cases _ O
, _ O
and _ O
the _ O
consequent _ O
withdrawal _ O
of _ O
restrictions _ O
across _ O
states _ O
. _ O

As _ O
a _ O
business _ O
, _ O
we _ O
did _ O
our _ O
bit _ O
to _ O
support _ O
in _ O
the _ O
battle _ O
against _ O
the _ O
COVID _ B-key
- _ I-key
19 _ I-key
pandemic _ B-key
. _ O

We _ O
worked _ O
in _ O
close _ O
collaboration _ O
with _ O
the _ O
government _ O
agencies _ O
and _ O
our _ O
marketing _ O
partners _ O
to _ O
ensure _ O
a _ O
consistent _ O
supply _ O
of _ O
medicines _ O
. _ O

Several _ O
supply _ B-key
chain _ I-key
optimization _ O
measures _ O
were _ O
incorporated _ O
from _ O
time _ O
to _ O
time _ O
, _ O
including _ O
included _ O
change _ O
of _ O
supply _ O
vendors _ O
, _ O
batch _ O
size _ O
modifications _ O
and _ O
changes _ O
to _ O
the _ O
manufacturing _ B-key
lines _ O
. _ O

I _ O
am _ O
happy _ O
to _ O
share _ O
that _ O
we _ O
maintained _ O
our _ O
growth _ O
momentum _ O
in _ O
FY _ O
2021 _ O
- _ O
22 _ O
with _ O
an _ O
emphasis _ O
on _ O
new _ B-key
product _ I-key
launches _ O
, _ O
life _ O
cycle _ O
management _ B-key
of _ O
products _ O
and _ O
focus _ O
on _ O
revenue _ B-key
diversification _ O
across _ O
geographies _ O
. _ O

Working _ O
together _ O
as _ O
a _ O
team _ O
to _ O
battle _ O
the _ O
COVID _ B-key
- _ I-key
19 _ I-key
pandemic _ B-key
, _ O
our _ O
workforce _ O
understands _ O
the _ O
impact _ O
their _ O
work _ O
makes _ O
in _ O
supporting _ O
the _ O
healthcare _ O
infrastructure _ O
globally _ O
and _ O
their _ O
collective _ O
efforts _ O
have _ O
helped _ O
Gland _ O
to _ O
report _ O
stronger _ O
financial _ B-key
performances _ O
across _ O
markets _ B-key
- _ O
proving _ O
our _ O
resilience _ O
to _ O
achieve _ O
steady _ O
progress _ O
. _ O

Core _ B-key
markets _ I-key
The _ O
US _ O
market _ O
has _ O
seen _ O
increased _ O
competition _ O
but _ O
at _ O
the _ O
same _ O
time _ O
shortages _ O
persist _ O
. _ O

While _ O
price _ B-key
erosion _ O
was _ O
noticed _ O
in _ O
certain _ O
recently _ O
genericized _ O
molecules _ O
, _ O
the _ O
mature _ O
portfolio _ O
remained _ O
stable _ O
. _ O

We _ O
continue _ O
to _ O
maintain _ O
our _ O
market _ B-key
share _ I-key
and _ O
have _ O
remained _ O
insulated _ O
from _ O
competitive _ O
pressures _ O
during _ O
the _ O
year _ O
. _ O

Our _ O
focus _ O
continues _ O
to _ O
remain _ O
on _ O
expanding _ O
our _ O
product _ O
portfolio _ O
to _ O
include _ O
differentiated _ O
products _ O
in _ O
the _ O
market _ O
. _ O

Besides _ O
, _ O
our _ O
R _ O
& _ O
D _ O
spends _ O
have _ O
been _ O
in _ O
line _ O
with _ O
our _ O
growth _ O
plans _ O
. _ O

We _ O
delivered _ O
a _ O
strong _ O
performance _ O
in _ O
the _ O
US _ O
market _ O
during _ O
FY _ O
2021 _ O
- _ O
22 _ O
with _ O
growth _ O
in _ O
existing _ O
product _ O
lines _ O
and _ O
new _ B-key
product _ I-key
launches _ O
. _ O

Our _ O
R _ O
& _ O
D _ O
efforts _ O
have _ O
also _ O
helped _ O
us _ O
maintain _ O
a _ O
strong _ O
momentum _ O
. _ O

We _ O
launched _ O
a _ O
total _ O
of _ O
44 _ O
product _ O
SKUs _ O
( _ O
29 _ O
molecules _ O
) _ O
during _ O
FY _ O
2021 _ O
- _ O
22 _ O
. _ O

Other _ O
core _ B-key
markets _ I-key
of _ O
Europe _ O
, _ O
Canada _ O
, _ O
Australia _ O
and _ O
New _ O
Zealand _ O
have _ O
also _ O
demonstrated _ O
strong _ O
demand _ B-key
for _ O
our _ O
products _ O
. _ O

Rest _ O
of _ O
the _ O
World _ B-key
markets _ I-key
Our _ O
strategy _ B-key
of _ O
expanding _ O
our _ O
product _ O
portfolio _ O
in _ O
identified _ O
geographies _ O
has _ O
produced _ O
encouraging _ O
results _ O
for _ O
Rest _ O
of _ O
the _ O
World _ O
markets _ O
. _ O

The _ O
biggest _ O
contributors _ O
were _ O
the _ O
LatAm _ O
, _ O
GCC _ O
and _ O
other _ O
Asian _ O
countries _ O
. _ O

While _ O
supply _ B-key
chain _ I-key
disruptions _ O
were _ O
rampant _ O
around _ O
the _ O
world _ O
, _ O
our _ O
efficient _ O
supply _ B-key
chain _ I-key
management _ B-key
strategies _ B-key
, _ O
supported _ O
by _ O
best-in-class _ O
manufacturing _ B-key
infrastructure _ I-key
, _ O
enabled _ O
us _ O
to _ O
meet _ O
shorter _ O
lead _ O
times _ O
required _ O
for _ O
Rest _ O
of _ O
the _ O
World _ O
markets _ O
. _ O

I _ O
believe _ O
there _ O
is _ O
enough _ O
scope _ O
to _ O
further _ O
expand _ O
our _ O
reach _ O
, _ O
given _ O
the _ O
breadth _ O
of _ O
our _ O
product _ O
portfolio _ O
. _ O

We _ O
also _ O
lay _ O
importance _ O
on _ O
building _ O
long-term _ O
relationships _ O
with _ O
our _ O
marketing _ B-key
partners _ I-key
and _ O
it _ O
has _ O
helped _ O
us _ O
deliver _ O
sustainable _ O
growth _ O
. _ O

The _ O
year _ O
FY _ O
2021 _ O
- _ O
22 _ O
was _ O
marked _ O
by _ O
several _ O
challenging _ O
macro-economic _ B-key
and _ O
geo-political _ O
factors _ O
. _ O

Gland _ O
â€™ _ O
s _ O
excellent _ O
performance _ O
in _ O
such _ O
testing _ O
times _ O
is _ O
a _ O
testament _ O
to _ O
our _ O
strategic _ B-key
priorities _ O
and _ O
our _ O
ability _ O
to _ O
transform _ O
challenges _ O
into _ O
sustainable _ O
value-creation _ B-key
opportunities _ O
for _ O
all _ O
our _ O
stakeholders _ B-key
. _ O

Srinivas _ O
Sadu _ O
MD _ O
& _ O
CEO _ O
12 _ O
13 _ O
GLAND _ O
PHARMA _ O
LIMITED _ O
Annual _ B-key
Report _ I-key
2021 _ O
- _ O
22 _ O
Financial _ O
StatementsCorporate _ O
Overview _ O
06 _ O
- _ O
49 _ O
Statutory _ B-key
Reports _ I-key
50 _ O
- _ O
116 _ O
117 _ O
- _ O
237 _ O
Domestic _ B-key
market _ I-key
Our _ O
domestic _ B-key
sales _ I-key
grew _ O
on _ O
the _ O
back _ O
of _ O
strong _ O
demand _ B-key
for _ O
our _ O
existing _ B-key
products _ I-key
. _ O

We _ O
were _ O
committed _ O
to _ O
support _ O
the _ O
nation _ O
during _ O
the _ O
COVID _ B-key
- _ I-key
19 _ I-key
pandemic _ O
. _ O
and _ O
the _ O
sale _ B-key
of _ O
products _ O
used _ O
for _ O
the _ O
treatment _ O
of _ O
COVID _ O
patients _ O
helped _ O
to _ O
ramp _ O
up _ O
revenues _ B-key
towards _ O
the _ O
beginning _ O
of _ O
the _ O
financial _ O
year _ O
. _ O

Manufacturing _ B-key
To _ O
fulfil _ O
our _ O
growth _ O
objectives _ O
across _ O
geographies _ O
, _ O
it _ O
was _ O
essential _ O
to _ O
align _ O
our _ O
manufacturing _ B-key
capabilities _ O
. _ O

As _ O
on _ O
March _ O
31 _ O
, _ O
2022 _ O
, _ O
we _ O
have _ O
28 _ O
lines _ O
with _ O
a _ O
normalised _ O
capacity _ O
of _ O
nearly _ O
~ _ O
1,000 _ O
Mn _ O
units _ O
as _ O
against _ O
~ _ O
800 _ O
Mn _ O
units _ O
last _ O
year _ O
. _ O

We _ O
have _ O
also _ O
added _ O
additional _ O
approved _ O
lines _ O
for _ O
our _ O
existing _ B-key
products _ I-key
to _ O
help _ O
reduce _ O
manufacturing _ B-key
risks _ O
. _ O

Our _ O
quality _ O
and _ O
regulatory _ O
teams _ O
have _ O
met _ O
stringent _ O
regulatory _ O
requirements _ O
and _ O
have _ O
ensured _ O
adherence _ O
to _ O
quality _ O
standards _ O
across _ O
operations _ O
. _ O

Last _ O
year _ O
, _ O
we _ O
were _ O
compelled _ O
to _ O
operate _ O
with _ O
a _ O
reduced _ O
workforce _ O
due _ O
to _ O
the _ O
pandemic _ B-key
. _ O

But _ O
, _ O
our _ O
dedication _ O
to _ O
uphold _ O
the _ O
highest _ O
quality _ O
standards _ O
enabled _ O
us _ O
to _ O
fulfil _ O
compliance _ O
requirements _ O
and _ O
our _ O
plants _ O
continue _ O
to _ O
be _ O
approved _ O
by _ O
the _ O
USFDA _ O
. _ O

Financial _ B-key
performance _ I-key
During _ O
the _ O
year _ O
, _ O
our _ O
consolidated _ O
revenue _ O
was _ O
H44,007 _ O
million _ O
with _ O
a _ O
revenue _ B-key
growth _ O
of _ O
27% _ O
over _ O
the _ O
previous _ O
year _ O
. _ O

Our _ O
EBITDA _ B-key
stood _ O
at _ O
H17,341 _ O
million _ O
as _ O
against _ O
H14,370 _ O
million _ O
in _ O
FY _ O
2020 _ O
- _ O
21 _ O
, _ O
reporting _ O
a _ O
growth _ O
of _ O
21% _ O
and _ O
our _ O
PAT _ B-key
was _ O
H12,117 _ O
million _ O
, _ O
increasing _ O
by _ O
22% _ O
over _ O
the _ O
previous _ O
year _ O
. _ O

We _ O
also _ O
achieved _ O
a _ O
revenue _ B-key
growth _ O
of _ O
16% _ O
across _ O
our _ O
core _ B-key
markets _ I-key
of _ O
the _ O
US _ O
, _ O
Canada _ O
, _ O
Europe _ O
, _ O
and _ O
Australia _ O
. _ O

We _ O
also _ O
registered _ O
revenue _ B-key
growth _ O
of _ O
13% _ O
in _ O
the _ O
US _ O
market _ O
. _ O

Alongside _ O
, _ O
Rest _ O
of _ O
the _ O
World _ B-key
market _ I-key
recorded _ O
a _ O
robust _ O
growth _ O
of _ O
55% _ O
. _ O

The _ O
Indian _ O
market _ O
also _ O
witnessed _ O
significant _ O
revenue _ B-key
growth _ O
of _ O
60% _ O
. _ O

Social _ O
commitments _ O
We _ O
are _ O
dedicated _ O
to _ O
fulfil _ O
our _ O
social _ O
obligations _ O
as _ O
a _ O
responsible _ O
corporate _ O
entity _ O
. _ O

Gland _ O
broadly _ O
focuses _ O
on _ O
serving _ O
the _ O
society _ O
by _ O
providing _ O
Education _ O
, _ O
healthcare _ O
facility _ O
, _ O
and _ O
ensuring _ O
the _ O
conservation _ O
of _ O
the _ O
environment _ O
, _ O
ecosystems _ O
and _ O
the _ O
natural _ O
resources _ O
. _ O

We _ O
also _ O
lay _ O
utmost _ O
importance _ O
on _ O
the _ O
safety _ O
and _ O
well _ O
- _ O
being _ O
of _ O
our _ O
employees _ O
. _ O

Our _ O
responsibility _ O
towards _ O
people _ O
, _ O
patients _ O
, _ O
communities _ O
and _ O
the _ O
natural _ O
environment _ O
override _ O
our _ O
business _ O
endeavours _ O
. _ O

To _ O
deliver _ O
exceptional _ O
outcomes _ O
and _ O
foster _ O
mutually _ O
beneficial _ O
relationships _ O
, _ O
we _ O
are _ O
committed _ O
to _ O
make _ O
positive _ O
changes _ O
to _ O
the _ O
lives _ O
of _ O
our _ O
stakeholders _ O
. _ O

Our _ O
CSR _ O
initiatives _ O
act _ O
as _ O
an _ O
impetus _ O
for _ O
creating _ O
value _ B-key
for _ O
communities _ O
and _ O
the _ O
society _ O
at _ O
large _ O
. _ O

We _ O
have _ O
allocated _ O
nearly _ O
H200 _ O
million _ O
on _ O
CSR _ O
initiatives _ O
during _ O
the _ O
last _ O
year _ O
on _ O
key _ O
projects _ O
encompassing _ O
education _ O
, _ O
health _ O
, _ O
and _ O
wildlife _ O
conservation _ O
. _ O

We _ O
We _ O
also _ O
supported _ O
the _ O
development _ O
of _ O
government _ O
school _ O
infrastructure _ O
and _ O
it _ O
benefitted _ O
nearly _ O
1530 _ O
students _ O
. _ O

During _ O
the _ O
second _ O
wave _ O
of _ O
Covid _ O
- _ O
19 _ O
we _ O
contributed _ O
towards _ O
building _ O
robust _ O
healthcare _ O
infrastructure _ O
by _ O
distributing _ O
ventilators _ O
, _ O
Masks _ O
, _ O
PPE _ O
Kits _ O
, _ O
Oxygen _ O
Cylinders _ O
, _ O
etc _ O
. _ O
at _ O
various _ O
hospitals _ O
. _ O

Road _ O
ahead _ O
Our _ O
near-term _ O
focus _ O
remains _ O
on _ O
establishing _ O
a _ O
strong _ O
portfolio _ O
of _ O
complex _ O
injectables _ O
. _ O

We _ O
are _ O
expanding _ O
capabilities _ O
in _ O
peptides _ O
, _ O
long _ O
acting _ O
injectables _ O
, _ O
suspensions _ O
and _ O
hormonal _ O
products _ O
with _ O
new _ O
delivery _ O
systems _ O
such _ O
as _ O
pens _ O
and _ O
cartridges _ O
. _ O

We _ O
are _ O
steadily _ O
investing _ B-key
towards _ O
creating _ O
robust _ O
infrastructure _ O
for _ O
Biologic _ O
CDMO _ O
. _ O

We _ O
have _ O
a _ O
team _ O
of _ O
experienced _ O
professionals _ O
to _ O
take _ O
this _ O
business _ O
forward _ O
. _ O

We _ O
are _ O
also _ O
exploring _ O
opportunities _ O
to _ O
collaborate _ O
with _ O
our _ O
partners _ O
and _ O
other _ O
companies _ O
to _ O
expedite _ O
our _ O
entry _ O
in _ O
this _ O
space _ O
. _ O

Over _ O
the _ O
years _ O
, _ O
we _ O
have _ O
delivered _ O
differentiated _ O
products _ O
with _ O
a _ O
Quality _ O
First _ O
approach _ O
. _ O

By _ O
continuing _ O
to _ O
evolve _ O
through _ O
manufacturing _ B-key
excellence _ O
, _ O
process _ O
improvement _ O
, _ O
regulatory _ O
compliance _ O
and _ O
best-in-class _ O
products _ O
, _ O
we _ O
continue _ O
to _ O
create _ O
long-term _ O
value _ O
for _ O
all _ O
our _ O
stakeholders _ B-key
. _ O

Before _ O
I _ O
conclude _ O
, _ O
let _ O
us _ O
look _ O
at _ O
some _ O
key _ O
priorities _ O
for _ O
2022 _ O
- _ O
23 _ O
: _ O
In _ O
terms _ O
of _ O
our _ O
operational _ O
performance _ O
, _ O
I _ O
clearly _ O
expect _ O
us _ O
to _ O
show _ O
steady _ O
improvements _ O
in _ O
financial _ B-key
performance _ I-key
our _ O
2023 _ O
targets _ O
. _ O

We _ O
will _ O
continue _ O
to _ O
actively _ O
manage _ O
our _ O
portfolio _ O
and _ O
enhance _ O
value _ B-key
creation _ I-key
for _ O
our _ O
shareholders _ B-key
. _ O

As _ O
We _ O
also _ O
look _ O
forward _ O
to _ O
grow _ O
Gland _ O
Pharma _ O
through _ O
suitable _ O
acquisitions _ O
that _ O
add _ O
strength _ O
to _ O
our _ O
existing _ O
business _ O
. _ O

Finally _ O
, _ O
looking _ O
at _ O
capital _ O
allocation _ O
, _ O
we _ O
expect _ O
a _ O
meaningful _ O
uplift _ O
in _ O
cash _ B-key
generation _ O
in _ O
FY _ O
2022 _ O
- _ O
23 _ O
and _ O
our _ O
capital _ O
allocation _ O
priorities _ O
remain _ O
unchanged _ O
. _ O

We _ O
will _ O
continue _ O
to _ O
focus _ O
on _ O
our _ O
investments _ B-key
in _ O
to _ O
R _ O
& _ O
D _ O
& _ O
Manufacturing _ B-key
to _ O
drive _ O
organic _ O
growth _ O
and _ O
execute _ O
value-accretive _ O
acquisitions _ O
to _ O
drive _ O
inorganic _ O
growth _ O
. _ O

Gland _ O
is _ O
one _ O
of _ O
the _ O
leading _ O
generic _ O
injectable _ O
CDMO _ O
companies _ O
, _ O
and _ O
we _ O
seek _ O
to _ O
sustain _ O
our _ O
position _ O
as _ O
a _ O
valued _ O
partner _ O
for _ O
our _ O
clients _ O
. _ O

Relying _ O
on _ O
our _ O
global _ O
R _ O
& _ O
D _ O
capabilities _ O
, _ O
manufacturing _ B-key
infrastructure _ I-key
and _ O
innovative _ B-key
focus _ O
, _ O
we _ O
intend _ O
to _ O
fulfil _ O
customer _ B-key
expectations _ I-key
. _ O

Although _ O
supply _ B-key
chain _ I-key
disruptions _ O
may _ O
weigh _ O
on _ O
our _ O
near-term _ O
outlook _ O
, _ O
we _ O
look _ O
forward _ O
to _ O
remaining _ O
on _ O
track _ O
for _ O
sustainable _ O
growth _ O
. _ O

On _ O
behalf _ O
of _ O
everyone _ O
at _ O
Gland _ O
and _ O
our _ O
Board _ O
, _ O
I _ O
would _ O
like _ O
to _ O
thank _ O
you _ O
for _ O
your _ O
continued _ O
support _ O
and _ O
trust _ O
. _ O

Regards _ O
Srinivas _ O
Sadu _ O
MD _ O
& _ O
CEO _ O

